Antidepressant

Firefly Neuroscience’s White Paper Unveils BNA™ Platform’s Significant Impact on Disease Management in 2,253 U.S Patients

Retrieved on: 
Tuesday, March 5, 2024
BNA, Transcranial magnetic stimulation, My Little Pony, AI, FDA, WAVD, Psychiatry, GAD, Antidepressant, EEG, Patient, Attention deficit hyperactivity disorder, DSM-IV codes, ADHD, MDD, Depression

FAIRFAX, Va. and TORONTO, March 05, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly”), a pioneering AI company developing innovative neuroscientific solutions to improve outcomes for patients with mental illnesses and neurological disorders, today announced the findings presented in a 2023 white paper “Brain Network Analytics (BNA) in the Psychiatric Practice: Real-Life Data Analysis” by Charlotte Baumeister, Ph.D., with analysis by Offir Laufer, Ph.D. Firefly has entered into an agreement (as amended, the “Merger Agreement”) to merge with WaveDancer, Inc. (“WaveDancer”) (NASDAQ: WAVD), subject to the approval of the stockholders of Firefly and WaveDancer (the “Merger”).

Key Points: 
  • This FDA-approved 510(k) tool harnesses vast data sets, including thousands of normative, age-matched electroencephalogram (“EEG”) recordings, empowering clinicians to make informed decisions in therapy and disease management.
  • The results suggest the transformative potential of the BNA™ Platform to significantly improve psychiatric care.
  • With the potential to revolutionize disease management, enhance treatment outcomes, and improve the overall well-being of patients with mental illnesses and cognitive disorders, we believe the BNA™ Platform can have a transformative impact.
  • We believe these findings will pave the way for widespread adoption of the BNA™ Platform into standard patient management protocols.”

Circular Genomics Announces Two Significant Steps Forward in Linking CircRNA to the Detection, Therapy Selection and Monitoring of Depressive Conditions

Retrieved on: 
Tuesday, July 11, 2023
Depression, Small RNA, CSO, Genomics, Antares, DRS, Brain, Biomarker, RNA, Trial of the century, CLIA, University of Texas Southwestern Medical Center, Patient, Blood, COVID-19, EMBARC, Diagnosis, Antidepressant, SSRI, Mental health, Pharmaceutical industry, Sertraline

“We’re excited to announce the findings from the EMBARC study and the ways in which we expect it to shape the future of depression treatment,” said Dr. Nikolaos Mellios, co-founder and CSO of Circular Genomics.

Key Points: 
  • “We’re excited to announce the findings from the EMBARC study and the ways in which we expect it to shape the future of depression treatment,” said Dr. Nikolaos Mellios, co-founder and CSO of Circular Genomics.
  • “While DNA-based pharmacogenomic tests are available, their ability to predict drug response or therapy monitoring is lacking and market adoption has been slow.
  • With our new findings, we can work to end the guessing game mental health patients currently have to go through.
  • In further developing its robust diagnostic and prognostic tests, Circular Genomics has closed an agreement with the ANTaRES consortium (The Biomarkers of ANTidepressant RESponse: early indicators and novel targets).

Circular Genomics Announces Two Significant Steps Forward in Linking CircRNA to the Detection, Therapy Selection and Monitoring of Depressive Conditions

Retrieved on: 
Tuesday, July 11, 2023
Depression, Small RNA, CSO, Genomics, Antares, DRS, Brain, Biomarker, RNA, Trial of the century, CLIA, University of Texas Southwestern Medical Center, Patient, Blood, COVID-19, EMBARC, Diagnosis, Antidepressant, SSRI, Mental health, Pharmaceutical industry, Sertraline

“We’re excited to announce the findings from the EMBARC study and the ways in which we expect it to shape the future of depression treatment,” said Dr. Nikolaos Mellios, co-founder and CSO of Circular Genomics.

Key Points: 
  • “We’re excited to announce the findings from the EMBARC study and the ways in which we expect it to shape the future of depression treatment,” said Dr. Nikolaos Mellios, co-founder and CSO of Circular Genomics.
  • “While DNA-based pharmacogenomic tests are available, their ability to predict drug response or therapy monitoring is lacking and market adoption has been slow.
  • With our new findings, we can work to end the guessing game mental health patients currently have to go through.
  • In further developing its robust diagnostic and prognostic tests, Circular Genomics has closed an agreement with the ANTaRES consortium (The Biomarkers of ANTidepressant RESponse: early indicators and novel targets).

Global Pain Management Drugs Market Report 2022-2027: Rise in Incidences of Chronic Diseases & Favorable Regulatory Scenario Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 10, 2022
Health, Pharmaceutical, Risk, Others, Industry, Antidepressant, Ansoff Matrix, Pain scale, Growth, Investment, NSAIDS, Arthritis, Cancer pain, SWOT, Geography, CAGR, Neuropathic pain, Migraine, Market development, USD, Poultry, Fibromyalgia, Anesthetic, Anticonvulsant

The Global Pain Management Drugs Market is segmented based on Drug Class, Indication, Pain Type, and Geography.

Key Points: 
  • The Global Pain Management Drugs Market is segmented based on Drug Class, Indication, Pain Type, and Geography.
  • By Indication, the market is classified into Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Back Pain, Post-Operative Pain, Migraine, Fibromyalgia, Bone Fracture, Muscle Sprain/Strain, Acute Appendicitis, and Others.
  • The report presents a detailed Ansoff matrix analysis for the Global Pain Management Drugs Market.
  • The analyst analyses the Global Pain Management Drugs Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.

Wesana Health Outlines Accelerated Drug Development Pathway

Retrieved on: 
Tuesday, May 10, 2022
COVID-19, Failure, Bipolar disorder, Elgin Mental Health Center, Company, Biotechnology, Antidepressant, Patient, Risk, Market share, Clinical trial, FDA, Non-governmental organization, Phrase, Health, Hospital, MDD, News, Research, Consultant, Central nervous system, SEDAR, Pharmaceutical industry

Except for statements of historical fact, information contained herein constitutes forward-looking information.

Key Points: 
  • Except for statements of historical fact, information contained herein constitutes forward-looking information.
  • Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management at the date the statements are made.
  • Depression Treatment Market By Drug Type (Antidepressants, Antipsychotics) By Application (Major Depressive Disorder (MDD), Bipolar Disorder), By End-User (Hospitals, NGOs, Mental Health Centers), By Distribution Channel, and By Region, Forecasts to 2027.
  • Emergen Research,

GABA Therapeutics Appoints Mario David Saltarelli M.D., Ph.D. as CEO and CMO

Retrieved on: 
Thursday, April 7, 2022
Private Securities Litigation Reform Act, Therapy, Amnesia, Life, Psychiatry, Lorazepam, GABA, Patent, Alprazolam, Mental health, Risk, Lists of diseases, Pharmacokinetics, RAAD, Antidepressant, CMO, Pharmacology, Benzodiazepine, CNS, SEC, Atai, AbbVie, CEO, U.S. Securities and Exchange Commission, Addiction, Pfizer, Biology, Technology, Securities Exchange Act of 1934, Securities Act of 1933, Epilepsy, GLOBE, List of life sciences, Strategic planning, Anxiety, Essential tremor, Ataxia, Central nervous system disease, News, Depression, Annual report, Patient, Security (finance), Pharmaceutical industry, Audit

NEWPORT BEACH, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- GABA Therapeutics, Inc, (GABA) a clinical-stage biotechnology company developing novel therapies for anxiety, depression and other neurological disorders, and part of the atai Life Sciences (atai) platform, announces the appointment of Mario David Saltarelli M.D., Ph.D. as Chief Executive Officer (CEO) and Chief Medical Officer (CMO) effective April 4, 2022.

Key Points: 
  • NEWPORT BEACH, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- GABA Therapeutics, Inc, (GABA) a clinical-stage biotechnology company developing novel therapies for anxiety, depression and other neurological disorders, and part of the atai Life Sciences (atai) platform, announces the appointment of Mario David Saltarelli M.D., Ph.D. as Chief Executive Officer (CEO) and Chief Medical Officer (CMO) effective April 4, 2022.
  • GABA Therapeutics, an atai Life Sciences platform company, is a clinical stage biotechnology company focused on addressing the growing, unmet medical need in serious psychiatric and neurological disorders, including depression, anxiety, epilepsy, and essential tremor.
  • This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended.
  • All references in these Forward-Looking Statements to we, and our, refer to GABA and atai, as applicable.

New Study Published in Nature Journal, Translational Psychiatry, by Taliaz, Presents New Approach for Predicting Response to Depression Treatment

Retrieved on: 
Wednesday, July 21, 2021
Major depressive disorder, Health sciences, Psychiatry, Branches of biology, Psychiatric diagnosis, STAR*D, Treatment of depression, Pharmacogenomics, Antidepressant, Treatment-resistant depression

"Current practice for MDD treatment relies mainly on trial and error, with an estimated 4253% response rates for antidepressant use.

Key Points: 
  • "Current practice for MDD treatment relies mainly on trial and error, with an estimated 4253% response rates for antidepressant use.
  • The authors analyzed response patterns of more than 4500 patients to antidepressant medications in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study and the Pharmacogenomics Research Network Antidepressant Medication Pharmacogenomic Study (PGRN-AMPS).
  • "This peer-reviewed publication corroborates our unique approach for the design of the PREDICTIX prediction algorithm to optimize treatment for mental health.
  • The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: a meta-analysis.

Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences

Retrieved on: 
Friday, June 11, 2021
Research, Clinical trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Chemical compounds, GABAA receptor positive allosteric modulators, Psychoactive drugs, Anticonvulsants, Ketones, Pregnanes, Sterols, Organic compounds, Ganaxolone, Allosteric modulator, Antidepressant

Vice President, Clinical Development

Key Points: 
  • Vice President, Clinical Development
    Speakers: Scott Braunstein, M.D., Chief Executive Officer and Joe Hulihan, M.D., Chief Medical Officer
    All of the above public webcasts may be accessed through the Events & Presentations page of the Investors & Media section of the Marinus website, www.marinuspharma.com .
  • Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders.
  • Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects.
  • The company has initiated a Phase 3 trial in refractory status epilepticus.

Marinus Pharmaceuticals Reschedules First Quarter 2021 Financial Results Conference Call

Retrieved on: 
Thursday, May 13, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical trials, Psychoactive drugs, Drugs, GABAA receptor positive allosteric modulators, Neurochemistry, Ketones, Sedatives, Anticonvulsants, Chloroarenes, Ganaxolone, Antidepressant, Allosteric modulator, Ketamine

b'Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders.

Key Points: 
  • b'Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders.
  • Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects.
  • Ganaxolone is being developed in IV and oral dose formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings.
  • The company has initiated a Phase 3 trial in refractory status epilepticus.

Annals of Family Medicine: Psychotherapy and Pharmacotherapy are More Effective in Treating Depression when Paired Together in Primary Care

Retrieved on: 
Tuesday, May 11, 2021
Major depressive disorder, Psychiatric diagnosis, Psychotherapy, Pharmacotherapy, Management of depression, Antidepressant, Psychiatry, Medicine, Clinical medicine, Bipolar spectrum, Mood disorders, Dysthymia

b'ANN ARBOR, Mich., May 11, 2021 /PRNewswire/ -- Most patients with depression are treated in primary care, and the majority of those patients prefer psychotherapy over treatment that includes medication (i.e., pharmacotherapy).

Key Points: 
  • b'ANN ARBOR, Mich., May 11, 2021 /PRNewswire/ -- Most patients with depression are treated in primary care, and the majority of those patients prefer psychotherapy over treatment that includes medication (i.e., pharmacotherapy).
  • Primary care physicians, however, are more likely to prescribe antidepressants to their patients suffering from depression.\nAlthough studies have shown the effectiveness of psychotherapy in primary care patients, researchers haven\'t yet examined the effects of psychotherapy compared with pharmacotherapy, combined treatment, and other clinical scenarios in primary care.\nIn a study published in the May/June, 2021 issue of Annals of Family Medicine, researchers examined the effects of psychotherapy compared with pharmacotherapy, combined treatment, care-as-usual, waitlist, and pill placebo in primary care patients.\nThe study is led by Pim Cuijpers, Ph.D., professor of clinical psychology in the Department of Clinical, Neuro and Development Psychology at Vrije Universiteit, The Netherlands, and includes collaborating authors from Japan, Spain, the U.K. and New Zealand.\nThe team integrated the results of 58 randomized controlled trials involving 9,301 patients.
  • "Treatments in primary care must be organized so as to accommodate any of these treatments in response to patients\' preferences and values.
  • "\nPsychologic Treatment of Depression Compared With Pharmacotherapy and Combined Treatment in Primary Care: A Network Meta-Analysis\nVrije Universiteit Amsterdam, Department of Clinical, Neuro and Developmental Psychology; Amsterdam Public Health Research Institute; Vrije Universiteit, Amsterdam, The Netherlands.\nView original content to download multimedia: http://www.prnewswire.com/news-releases/annals-of-family-medicine-psycho...\n'